Bliss GVS has gained a leadership position in creating brands in Anti-malarial segment for Artemisinin-based Combination Therapy like Artemether/Lumefantrine (AL), the fixed-dose recommended & pre-qualified by WHO for the treatment of uncomplicated malaria caused by Plasmodium falciparum. We also manufacture anti-malarial tablets in fixed-dose combinations (co-formulated) and co-packaged products like Artesunate 50 mg + Amodiaquine 153.1mg Tablets. Lonart is our flagship brand in the anti-malarial segment that enjoys a dominant position across markets in Africa.
Along with the Anti-malarial segment, we are also developing our brands in other therapeutic segments like Cardiovascular, Anti-Diabetics, Anti-hypertensive, Anti-biotics, Anti-inflammatory, Analgesic and Erectile Dysfunction.